Daridorexant + Placebo
Phase 1Completed 2 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obstructive Sleep Apnea of Adult
Conditions
Obstructive Sleep Apnea of Adult
Trial Timeline
Aug 17, 2022 → Feb 28, 2023
NCT ID
NCT05458193About Daridorexant + Placebo
Daridorexant + Placebo is a phase 1 stage product being developed by Idorsia for Obstructive Sleep Apnea of Adult. The current trial status is completed. This product is registered under clinical trial identifier NCT05458193. Target conditions include Obstructive Sleep Apnea of Adult.
What happened to similar drugs?
20 of 20 similar drugs in Obstructive Sleep Apnea of Adult were approved
Approved (20) Terminated (2) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
6
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05597020 | Approved | Completed |
| NCT05458193 | Phase 1 | Completed |
Competing Products
20 competing products in Obstructive Sleep Apnea of Adult